Clinical features and prognosis of retroperitoneal hemangiosarcoma in dogs with surgical resection with or without adjuvant doxorubicin

Masanao ICHIMATA; Atsushi TOSHIMA; Fukiko MATSUYAMA; Eri FUKAZAWA; Kei HARADA; Ryuzo KATAYAMA; Yumiko KAGAWA; Tetsushi YAMAGAMI; Tetsuya KOBAYASHI

doi:10.1292/jvms.22-0533

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Clinical features and prognosis of retroperitoneal hemangiosarcoma in dogs with surgical resection with or without adjuvant doxorubicin

Masanao ICHIMATA, Atsushi TOSHIMA, Fukiko MATSUYAMA, Eri FUKAZAWA, Kei HARADA, Ryuzo KATAYAMA, Yumiko KAGAWA, Tetsushi YAMAGAMI, Tetsuya KOBAYASHI

著者情報

Masanao ICHIMATA
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation
Atsushi TOSHIMA
Japan Small Animal Medical Center
Fukiko MATSUYAMA
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation
Eri FUKAZAWA
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation
Kei HARADA
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation
Ryuzo KATAYAMA
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation
Yumiko KAGAWA
Japan Small Animal Medical Center
North Lab.
Tetsushi YAMAGAMI
Japan Small Animal Medical Center
Tetsuya KOBAYASHI
Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation

キーワード: dog, doxorubicin, hemangiosarcoma, retroperitoneum, surgery

ジャーナルオープンアクセス早期公開

論文ID: 22-0533

DOI https://doi.org/10.1292/jvms.22-0533

この記事には本公開記事があります。

The final version of this article is now available: Vol. 85 (2023), No. 11 pp. 1231-1236

詳細

抄録

Retroperitoneal hemangiosarcoma (RPHSA) is a rare tumor in dogs with a poorly understood prognosis after surgery. The objectives of this study were to investigate the clinical features and prognosis of canine RPHSA that had undergone surgical resection. In this single-center, retrospective cohort study, we reviewed the medical records of dogs that had undergone surgical resection for retroperitoneal tumors and received a histopathologic diagnosis of HSA between 2005 and 2021. The median progression-free survival (PFS) and overall survival (OS) were 77.5 days and 168 days, respectively. In the present study, canine RPHSA had an aggressive biological behavior similar to visceral HSA. Further studies in larger canine populations are needed to evaluate the efficacy of adjuvant chemotherapy.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）